Who is sponsoring NCT04149886?

NCT04149886 is sponsored by China National Center for Cardiovascular Diseases.

What condition does NCT04149886 study?

NCT04149886 studies Cardioneuroablation, Permanent Pacemaker Implantation, Sick Sinus Syndrome, Ganglionated Plexus.

Is NCT04149886 still recruiting?

NCT04149886 is currently status unknown. Last updated 4 November 2019.

Last reviewed 2019-11-04 · How we verify

NCT04149886: GAPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cardiac Ganglionated Plexus Ablation Before Permanent Pacemaker Implantation in Patients With Sick Sinus Syndrome

Status unknown NA Last updated 4 November 2019

What this trial tests

NA trial testing cardiac ganglion plexus ablation(cardioneuroablation) in Cardioneuroablation in 100 participants. Status unknown.

Timeline

28 October 2019

Primary endpoint
27 October 2020

27 October 2021

Quick facts

Lead sponsor	China National Center for Cardiovascular Diseases
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	100
Start date	28 October 2019
Primary completion	27 October 2020
Estimated completion	27 October 2021
Sites	2 locations across China

Drugs / interventions tested

cardiac ganglion plexus ablation(cardioneuroablation)
Permanent pacemaker implantation

Conditions studied

Cardioneuroablation — all drugs for Cardioneuroablation →
Permanent Pacemaker Implantation — all drugs for Permanent Pacemaker Implantation →
Sick Sinus Syndrome — all drugs for Sick Sinus Syndrome →
Ganglionated Plexus — all drugs for Ganglionated Plexus →

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

Adults 14 to 75, any sex, with Cardioneuroablation or Permanent Pacemaker Implantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Different studies for cardiac ganglionated plexus（GP） ablation to treat vagal vascular syncope, sinus node dysfunction, and functional atrioventricular block have been published. Investigators have developed a more specific approach of cardiac, called cardioneuroablation . This treatment is based on a high-frequency stimulation (HFS) and/or anatomical landmarks to identify GPs in left atrium，which being targeted by radiofrequency catheter ablation. The feasibility of GPs ablation/cardioneuroablation has already been tested in our center in former studies in humans,with a favorable outcome for the patients involved. The results of the former studies have been submitted for publication. However, there are no prospective randomized studies to evaluate the efficacy and safety of atrial ganglionated plexus ablation for SSS before permanent pacemaker implantation. The purpose of this study of GAPS in humans is to evaluate the efficacy and safety of cardioneuroablation in patients of sick sinus syndrome before they receive a permanent pacemaker.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart R
Aksu T, Brignole M, Calo L, Debruyne P, et al · · 2024 · cited 45× · PMID 39082698 · DOI 10.1093/europace/euae206
Cardioneuroablation: Where are we at?
Pachon JC, Pachon EI, Aksu T, Gopinathannair R, et al · · 2023 · cited 27× · PMID 37361615 · DOI 10.1016/j.hroo.2023.02.007
Cardioneuroablation: A Comprehensive Review
Conti S, Porto A, Zappulla P, Sgarito G. · · 2026

Verify or expand the search:

Other trials of cardiac ganglion plexus ablation(cardioneuroablation)

Trials testing the same drug.

NCT05573178 — Different Catheter Ablation Strategy in Vasovagal Syncope · NA · completed

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

NCT07514988 — Sirolimus-Coated vs Paclitaxel-Coated DCBs in ACS Treatment · NA · not yet recruiting
NCT07476456 — Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death · not yet recruiting
NCT07302659 — Aortic No-Touch vs Partial Aortic Clamping in Off-Pump CABG · NA · recruiting
NCT07482683 — Predicting Post-Cardiac Surgery Acute Kidney Disease: A Machine Learning Approach · not yet recruiting
NCT06787430 — Effects of Nicorandil on Microvascular Dysfunction in Patients With STEMI Undergoing Primary PCI · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04149886 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China National Center for Cardiovascular Diseases
Last refreshed: 4 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04149886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing